Timing of Adjuvant Therapy

Part of the Cancer Treatment and Research book series (CTAR, volume 151)


Breast Cancer Hazard Rate LHRH Agonist Tumour Dormancy Primary Endocrine Therapy 


  1. 1.
    Jatoi I, Chen BE, Anderson WF, Rosenberg PS. Breast Cancer Mortality Trends in the United States According to Estrogen Receptor Status and Age at Diagnosis. J Clin Oncol. 2007;25:1683–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Sorlie T. Molecular classification of breast tumors: Toward improved diagnostics and treatments. Methods Mol Biol. 2007;360:91–114.PubMedGoogle Scholar
  3. 3.
    Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist. 2003;8:307–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Slamon DJ, Godolphin W, Jones LA, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Burstein HJ, Lieberman G, Slamon DJ, et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005;16:1772–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant polychemotherapy in oestrogen-receptor-poor breast cancer: meta-analysis of individual patient data from the randomised trials. Submitted to The Lancet 10 April 2007.Google Scholar
  7. 7.
    Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1658–67.PubMedCrossRefGoogle Scholar
  8. 8.
    Pujol P, Daures JP, Brouillet JP, et al. A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma. Cancer. 2001;91(10):1854–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Milella M, Nistico C, Ferraresi V, et al. Breast cancer and timing of surgery during menstrual cycle: A 5-year analysis of 248 premenopausal women. Breast Cancer Res Treat. 1999;55(3):259–66.PubMedCrossRefGoogle Scholar
  10. 10.
    Thorpe H, Brown SR, Sainsbury JR et al. Timing of breast cancer surgery in relation to menstrual cycle phase: No effect on 3-year prognosis: The ITS Study. BJC. 2008;98:39–44.Google Scholar
  11. 11.
    Chaudhry A, Puntis ML, Gikas P, Mokbel K. Does the timing of breast cancer surgery in pre-menopausal women affect clinical outcome? An update. International Seminars in Surgical Oncology. 2006;3:37.PubMedCrossRefGoogle Scholar
  12. 12.
    Goldhirsch A, Gelber RD, Castiglione M, et al. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol. 1997;8:751–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Macleod J, Fraser R, Horeczko N. Menses and breast cancer: Does timing of mammographically directed core biopsy affect outcome? J Surg Oncol. 2000;74(3):232–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:2540–5.CrossRefGoogle Scholar
  15. 15.
    Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2005;23:2694–702.PubMedCrossRefGoogle Scholar
  16. 16.
    Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 2009;16(5):551–63.Google Scholar
  17. 17.
    Stearns V, Ewing CA, Slack R, et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliable represent the axilla except for inflammatory patients. Ann Surg Oncol. 2002;9:235–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Jones JL, Zabicki K, Christian RL, et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: Timing is important. Am J Surg. 2005;190(4):517–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg. 1995;180:297–306.PubMedGoogle Scholar
  20. 20.
    Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast. 2003;12:320–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathological response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004;22:2284–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Benchalal M, Le Prise E, de Lafontan B, et al. Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: Results of the French Adjuvant Study Group. Cancer. 2005;104(2):240–50.PubMedCrossRefGoogle Scholar
  23. 23.
    Wallgren A, Bernier J, Gelber RD, et al. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. Int J Radiat Oncol Biol Phys. 1996;35(4):649–59.PubMedCrossRefGoogle Scholar
  24. 24.
    Arcangeli G, Pinnaro P, Rambone R, et al. A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2006;64(1):161–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Jobsen JJ, van der Palen J, Ong F, Meerwaldt JH. Timing of radiotherapy and survival benefit in breast cancer. Breast Cancer Res Treat. 2006;99(3):289–94.PubMedCrossRefGoogle Scholar
  26. 26.
    Vujovic O, Yu E, Cherian A, et al. Eleven-year follow-up results in the delay of breast irradiation after conservative breast surgery in node-negative breast cancer patients. Int J Radiat Oncol Biol Phys. 2006;64(3):760–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Fearmonti RM, Vicini FA, Pawlik TM, Kuerer HM. Integrating partial breast irradiation into surgical practice and clinical trials. Surg Clin North Am. 2007;87(2):485–98.PubMedCrossRefGoogle Scholar
  28. 28.
    Arthur DW, Morris MM, Vicini FA. Breast cancer: new radiation treatment options. Oncology. 2004;18(13):1621–9.PubMedGoogle Scholar
  29. 29.
    Isaac N, Panzarella T, Lau A, et al. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen. Cancer. 2002;95(4):696–703.PubMedCrossRefGoogle Scholar
  30. 30.
    Montemurro F, Gatti M, Redana S, et al. Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer. J Chemother. 2006;18(1):90–7.PubMedGoogle Scholar
  31. 31.
    Luini A, Gatti G, Zurrida S, et al. The evolution of the conservative approach to breast cancer. Breast. 2007;16(2):120–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Taghian AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001;93(23):1806–11.PubMedCrossRefGoogle Scholar
  33. 33.
    Ellerbroek N, Martino S, Mautner B, et al. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: Feasibility of concurrent treatment. Breast J. 2003;9(2):74–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer. The Oncologist. 2006;11(suppl 1):4–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Koukourakis MI, Manavis J, Simopoulos C, et al. Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer. Am J Clin Oncol. 2005;28(5):495–500.PubMedCrossRefGoogle Scholar
  36. 36.
    Schmidberger H, Hermann RM, Hess CF, Emons G. Interactions between radiation and endocrine therapy in breast cancer. Endocr Relat Cancer. 2003;10(3):375–88.PubMedCrossRefGoogle Scholar
  37. 37.
    Koc M, Polat P, Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol. 2002;64:171–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Wazer D, DiPetrillo T, Schmidt-Ullrich R, et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1992;10:356–63.PubMedGoogle Scholar
  39. 39.
    Ahn PH, Vu HT, Lannin D, et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol. 2005;23(1):17–23.PubMedCrossRefGoogle Scholar
  40. 40.
    Harris EER, Christensen VJ, Hwang WT, et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol. 2005;23:11–16.PubMedCrossRefGoogle Scholar
  41. 41.
    Pierce LJ, Hutchins LF, Green SR, et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005;23:24–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Azria D, Larbouret C, Cunat S, et al. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res. 2005;7(1):R156–63.PubMedCrossRefGoogle Scholar
  43. 43.
    White DE, Rayment JH, Muller WJ. Addressing the role of cell adhesion in tumour cell dormancy. Cell Cycle. 2006;5(16):1756–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): An essential player in multiple games of cancer: a review on its role in tumour progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle. 2006;5(16):1760–71.PubMedCrossRefGoogle Scholar
  45. 45.
    Ranganathan AC, Adam AP, Aguirre-Ghiso JA. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle. 2006;5(16):1799–807.PubMedCrossRefGoogle Scholar
  46. 46.
    Fisher B, Saffer EA, Rudok C, et al. Presence of a growth-stimulating factor in serum following primary tumour removal in mice. Cancer Res. 1989;49:1996–2001.PubMedGoogle Scholar
  47. 47.
    Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumour dormancy: Animal models of the angiogenic switch. Cell Cycle. 2006;5(16):1779–87.PubMedCrossRefGoogle Scholar
  48. 48.
    Marches R, Scheuermann R, Uhr J. Cancer dormancy: From mice to man. Cell Cycle. 2006;5(16):1772–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Muller V, Hayes DF, Pantel K. Recent translational research: circulating tumour cells in breast cancer patients. Breast Cancer Res. 2006;8(5):110.PubMedCrossRefGoogle Scholar
  50. 50.
    Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8):793–802.PubMedCrossRefGoogle Scholar
  51. 51.
    McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet. 1995;346:1334–1335.PubMedCrossRefGoogle Scholar
  52. 52.
    Demicheli R, Miceli R, Moliterni A, et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumour dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol. 2005;16:1449–57.PubMedCrossRefGoogle Scholar
  53. 53.
    Retsky M, Bonadonna G, Demicheli R, et al. Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res. 2004;6(4):R372–R374.PubMedCrossRefGoogle Scholar
  54. 54.
    Klein CA. The systemic progression of human cancer: A focus on the individual disseminated cancer cell–the unit of selection. Adv Cancer Res. 2003;89:35–67.PubMedCrossRefGoogle Scholar
  55. 55.
    Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: Opportunities for new therapeutic approaches. Nat Med. 1997;3:505–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update. J Clin Oncol. 2006;24:1940–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst. 2005;97:188–94.PubMedCrossRefGoogle Scholar
  58. 58.
    Macaskill EJ, Dixon JM. Neoadjuvant use of endocrine therapy in breast cancer. Breast J. 2007;13(3):243–50.PubMedCrossRefGoogle Scholar
  59. 59.
    Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007 May 30.Google Scholar
  60. 60.
    Colleoni M, Viale G, Zahrieh D, et al. Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy. Ann Oncol. 2008;19:465–72.CrossRefGoogle Scholar
  61. 61.
    Carey LA, Dees EC, Sawyer L, et al. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin Cancer Res. 2007;13(8):2329–34.PubMedCrossRefGoogle Scholar
  62. 62.
    Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–85.PubMedCrossRefGoogle Scholar
  63. 63.
    Montemurro F, Aglietta M. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Clin Breast Cancer. 2005;6:77–80.PubMedCrossRefGoogle Scholar
  64. 64.
    Coudert BP, Largillier R, Arnould L, et al. Multicenter phase II trail of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol. 200;25(19):2678–84.Google Scholar
  65. 65.
    Limentani SA, Brufsky AM, Erban JK, et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2– overexpressing locally advanced breast cancer. J Clin Oncol. 2007;25:1232–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Hurley J, Doliny P, Reis I, et al. Docetaxel, Cisplatin, and Trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2–positive locally advanced breast cancer. J Clin Oncol. 2006;24:1831–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumours overexpressing HER2. Clin Cancer Res. 2004;10(17):5650–5.PubMedCrossRefGoogle Scholar
  68. 68.
    von Minckwitz G, Blohmer JU, Raab G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol. 2005;16:56–63.CrossRefGoogle Scholar
  69. 69.
    Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide ± filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21:843–50.PubMedCrossRefGoogle Scholar
  70. 70.
    Osborne CK, Kitten L, Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol. 1989;7(6):710–17.PubMedGoogle Scholar
  71. 71.
    Berman E, Adams M, Duigou-Osterndorf R, et al. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood. 1991;77:818–25.PubMedGoogle Scholar
  72. 72.
    Fisher B, Redmond C, Brown A, et al. Adjuvant chemotherapy with and without tamoxifen: Five-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol. 1986;4:459–71.PubMedGoogle Scholar
  73. 73.
    The International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol. 1997;15:1385–93.Google Scholar
  74. 74.
    Pico C, Martin M, Jara C. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: Randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol. 2004;15:79–87.PubMedCrossRefGoogle Scholar
  75. 75.
    Sertoli MR, Pronzato P, Venturini M, et al. A randomized study of concurrent versus sequential adjuvant chemotherapy and tamoxifen in stage II breast cancer. Proc Am Soc Clin Oncol. 2002;21:182.Google Scholar
  76. 76.
    Albain K, Barlow W, O'Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat. 2004;88:(abstr 37).Google Scholar
  77. 77.
    Del Mastro L, Dozin B, Aitini E, et al. Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest–Mammella Intergruppo (GONO-MIG) Group. Ann Oncol. 2008;19:299–307.Google Scholar
  78. 78.
    Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996;14:2731–7.PubMedGoogle Scholar
  79. 79.
    M. Colleoni M, Li S, Gelber RD, et al. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: Role of endocrine responsiveness of the tumor. Ann Oncol. 2005;16(5):716–25.PubMedCrossRefGoogle Scholar
  80. 80.
    Speer JF, Petrosky VE, Retsky MW, et al. A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res. 1984;44:4124–30.PubMedGoogle Scholar
  81. 81.
    Bellon JR, Come SE, Gelman RS. Sequencing of Chemotherapy and Radiation Therapy in Early-Stage Breast Cancer: Updated Results of a Prospective Randomized Trial. J Clin Oncol. 2005;23:1934–40.PubMedCrossRefGoogle Scholar
  82. 82.
    Cold S, During M, Ewertz M, et al. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer. 2005;93:627–32.PubMedCrossRefGoogle Scholar
  83. 83.
    Jara Sanchez C, Ruiz A, Martin M, et al. Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Res Treat. 2007;101(2):215–23.PubMedCrossRefGoogle Scholar
  84. 84.
    Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24:4888–94.PubMedCrossRefGoogle Scholar
  85. 85.
    Shannon C, Ashley S, Smith IE. Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol. 2003;21:3792–97.PubMedCrossRefGoogle Scholar
  86. 86.
    Brooks RJ, Jones SE, Salmon SE, et al. Adjuvant chemotherapy of axillary node-negative carcinoma of the breast using doxorubicin and cyclophosphamide. NCI Monogr. 1986;(1):135–7.Google Scholar
  87. 87.
    Pronzato P, Campora E, Amoroso D, et al. Impact of administration related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol. 1989;12:481–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Clahsen PC, van de Velde CJH, Goldhirsch A, et al. Overview of randomized perioperative polychemotherapy trials in women with early stage breast cancer. J Clin Oncol. 1997;15:2525–35.Google Scholar
  89. 89.
    van der Hage JA, van de Velde CJ, Julien JP, et al. Improved survival after one course of perioperative chemotherapy in early breast cancer patients. long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854. Eur J Cancer. 2001;37(17):2184–93.PubMedCrossRefGoogle Scholar
  90. 90.
    The Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer: Inadequacy of a single perioperative cycle. N Engl J Med. 1988;319:677–83.Google Scholar
  91. 91.
    Colleoni M, Bonetti M, Coates AS, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors: The International Breast Cancer Study Group. J Clin Oncol. 2000;18:584–90.PubMedGoogle Scholar
  92. 92.
    Colleoni M, Gelber S, Coates AS, et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node–negative breast cancer. J Clin Oncol. 2001;19:4141–9.PubMedGoogle Scholar
  93. 93.
    Henderson IC, Gelman RS, Harris JR, et al. Duration of therapy in adjuvant chemotherapy trials. NCI Monogr. 1986;1:95–8.PubMedGoogle Scholar
  94. 94.
    International Breast Cancer Study Group: Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol. 1996;14:1885–94.Google Scholar
  95. 95.
    Sauerbrei W, Bastert G, Bojar H, et al. for the German Breast Cancer Study Group. Randomized 2 3 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: An Update Based on 10 Years’ Follow-Up. J Clin Oncol. 2000;18:94–101.PubMedGoogle Scholar
  96. 96.
    Colleoni M, Litman HJ, Castiglione-Gertsch M, et al. Duration of adjuvant chemotherapy for breast cancer: A joint analysis of two randomised trials investigating three versus six courses of CMF. International Breast Cancer Study Group; German Breast Cancer Study Group. Br J Cancer. 2002;86(11):1705–14.PubMedCrossRefGoogle Scholar
  97. 97.
    Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med. 1989;320:491–6.Google Scholar
  98. 98.
    International Breast Cancer Study Group. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13–93 and 14–93. Ann Oncol. Apr 11, 2007.Google Scholar
  99. 99.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet. 2005;365:1687–717.Google Scholar
  100. 100.
    Silliman RA, Ganz PA. Adjuvant chemotherapy use and outcomes in older women with breast cancer: What have we learned? J Clin Oncol. 2006;24(18):2697–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293:1073–81.PubMedCrossRefGoogle Scholar
  102. 102.
    Elkin EB, Hurria A, Mitra N, et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: Assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24:2757–64.PubMedCrossRefGoogle Scholar
  103. 103.
    Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol. 2000;18:1709–17.PubMedGoogle Scholar
  104. 104.
    Giordano SH, Duan Z, Kuo Y-F, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750–6.PubMedCrossRefGoogle Scholar
  105. 105.
    Goldhirsch A, Wood WC, Gelber RD, et al. and Panel Members. Progress and Promise: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2007. Ann Oncol (submitted).Google Scholar
  106. 106.
    Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials LHRH-agonists in Early Breast Cancer Overview group. Lancet. 2007;369:1711–23.PubMedCrossRefGoogle Scholar
  107. 107.
    Gray RG, Rea DW, Handley K, et al. aTTom (adjuvant Tamoxifen--To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer--Preliminary results. J Clin Oncol. 2008;26 (May 20 suppl; abstr 513)Google Scholar
  108. 108.
    Peto R, Davies C on Behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women – preliminary results. SABCS 2007 (abstr 48).Google Scholar
  109. 109.
    Coates AS, Keshaviah A, Thürlimann B, et al. Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. J Clin Oncol. 2007;25:486–92.PubMedCrossRefGoogle Scholar
  110. 110.
    Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100- month analysis of the ATAC trial. Lancet Oncol. 2008;(1):45–53.PubMedCrossRefGoogle Scholar
  111. 111.
    Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet. 2007;369:559–70.PubMedCrossRefGoogle Scholar
  112. 112.
    Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006;7:991–6.PubMedCrossRefGoogle Scholar
  113. 113.
    Goss PE, Ingle JN, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol. 2007;25:2006–11.PubMedCrossRefGoogle Scholar
  114. 114.
    Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al. BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. SABCS 2008, (abstr 13).Google Scholar
  115. 115.
    Mauriac L, Keshaviah A, Debled M, et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol. 2007;18:859–67.PubMedCrossRefGoogle Scholar
  116. 116.
    Viale G, Giobbie-Hurde Ar, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from breast international group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26:5569–75.Google Scholar
  117. 117.
    Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008;9:23–8.Google Scholar
  118. 118.
    Lewis JS, Osipo C, Meeke K, et al. Estrogen-induced apoptosis in breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol. 2005;94:131–41.PubMedCrossRefGoogle Scholar
  119. 119.
    Lonning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 2001;67:111–6.PubMedCrossRefGoogle Scholar
  120. 120.
    Saphner T, Tormey DC, Gray R. Annual recurrence hazard rates for breast cancer after adjuvant therapy annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–46.PubMedGoogle Scholar
  121. 121.
    Smith IE, Dowsett M, Yap YS, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and Suggested Guidelines. J Clin Oncol. 2006;24:2444–7.PubMedCrossRefGoogle Scholar
  122. 122.
    Perez EA, Suman VJ, Davidson N, et al. Advances in monoclonal therapy for breast cancer: Further analysis of NCCTG N9831. 41st Annual Meeting of the American Society of Clinical Oncology; Orlando: FL; May 16, 2005.Google Scholar
  123. 123.
    Halyard MY, Pisansky TM, Dueck AC, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: Tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol. 2009;27. Published Ahead of Print on April 6th.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Institute of Oncology of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, SwitzerlandInternational Breast Cancer Study Group (IBCSG) and Swiss Group for Clinical Cancer Research (SAKK)BernSwitzerland

Personalised recommendations